BSE:524742

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Caplin Point Laboratories Limited develops, manufactures, markets, and exports generic pharmaceutical formulations and branded generic products in India and internationally. More Details


Snowflake Analysis

Excellent balance sheet with proven track record.


Similar Companies

Share Price & News

How has Caplin Point Laboratories's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 524742's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-2.1%

524742

-1.7%

IN Pharmaceuticals

-0.6%

IN Market


1 Year Return

34.3%

524742

45.4%

IN Pharmaceuticals

0.9%

IN Market

Return vs Industry: 524742 underperformed the Indian Pharmaceuticals industry which returned 45.4% over the past year.

Return vs Market: 524742 exceeded the Indian Market which returned 0.9% over the past year.


Shareholder returns

524742IndustryMarket
7 Day-2.1%-1.7%-0.6%
30 Day-6.0%-0.8%4.0%
90 Day28.6%11.7%5.7%
1 Year35.2%34.3%47.2%45.4%2.6%0.9%
3 Year-21.5%-22.8%22.6%19.3%-2.8%-7.4%
5 Year112.2%107.1%-0.2%-3.7%39.9%29.5%

Price Volatility Vs. Market

How volatile is Caplin Point Laboratories's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Caplin Point Laboratories undervalued compared to its fair value and its price relative to the market?

17.88x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: 524742 (₹518.35) is trading above our estimate of fair value (₹348.01)

Significantly Below Fair Value: 524742 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: 524742 is good value based on its PE Ratio (17.9x) compared to the IN Pharmaceuticals industry average (22.8x).

PE vs Market: 524742 is poor value based on its PE Ratio (17.9x) compared to the Indian market (16.2x).


Price to Earnings Growth Ratio

PEG Ratio: 524742 is good value based on its PEG Ratio (0.9x)


Price to Book Ratio

PB vs Industry: 524742 is overvalued based on its PB Ratio (4.1x) compared to the IN Pharmaceuticals industry average (2.2x).


Next Steps

Future Growth

How is Caplin Point Laboratories forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

18.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 524742's forecast earnings growth (18.9% per year) is above the savings rate (7.2%).

Earnings vs Market: 524742's earnings (18.9% per year) are forecast to grow slower than the Indian market (25.6% per year).

High Growth Earnings: 524742's earnings are forecast to grow, but not significantly.

Revenue vs Market: 524742's revenue (16.4% per year) is forecast to grow faster than the Indian market (11.3% per year).

High Growth Revenue: 524742's revenue (16.4% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 524742's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Caplin Point Laboratories performed over the past 5 years?

30.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 524742 has high quality earnings.

Growing Profit Margin: 524742's current net profit margins (24.1%) are lower than last year (27.2%).


Past Earnings Growth Analysis

Earnings Trend: 524742's earnings have grown significantly by 30% per year over the past 5 years.

Accelerating Growth: 524742's earnings growth over the past year (15.7%) is below its 5-year average (30% per year).

Earnings vs Industry: 524742 earnings growth over the past year (15.7%) exceeded the Pharmaceuticals industry 14.7%.


Return on Equity

High ROE: 524742's Return on Equity (23%) is considered high.


Next Steps

Financial Health

How is Caplin Point Laboratories's financial position?


Financial Position Analysis

Short Term Liabilities: 524742's short term assets (₹8.2B) exceed its short term liabilities (₹1.4B).

Long Term Liabilities: 524742's short term assets (₹8.2B) exceed its long term liabilities (₹248.6M).


Debt to Equity History and Analysis

Debt Level: 524742's debt to equity ratio (3.8%) is considered satisfactory.

Reducing Debt: 524742's debt to equity ratio has increased from 2.2% to 3.8% over the past 5 years.

Debt Coverage: 524742's debt is well covered by operating cash flow (122.5%).

Interest Coverage: 524742's interest payments on its debt are well covered by EBIT (281.9x coverage).


Balance Sheet


Next Steps

Dividend

What is Caplin Point Laboratories's current dividend yield, its reliability and sustainability?

0.48%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: 524742's dividend (0.48%) isn’t notable compared to the bottom 25% of dividend payers in the Indian market (0.56%).

High Dividend: 524742's dividend (0.48%) is low compared to the top 25% of dividend payers in the Indian market (2.29%).


Stability and Growth of Payments

Stable Dividend: 524742's dividends per share have been stable in the past 10 years.

Growing Dividend: 524742's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its low payout ratio (8.6%), 524742's dividend payments are thoroughly covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

  • Explore strong dividend paying companies in the Pharmaceuticals & Biotech industry.

Management

How experienced are the management team and are they aligned to shareholders interests?

5.6yrs

Average management tenure


CEO

Sridhar Ganesan (65 yo)

5.58yrs

Tenure

₹5,686,000

Compensation

Dr. Sridhar Ganesan has been the Managing Director of Caplin Point Laboratories Ltd since March 28, 2015. Dr. Ganesan has been Whole Time Director of Caplin Point Laboratories Ltd since August 25, 2014. Dr ...


CEO Compensation Analysis

Compensation vs Market: Sridhar's total compensation ($USD76.90K) is below average for companies of similar size in the Indian market ($USD353.89K).

Compensation vs Earnings: Sridhar's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Sridhar Ganesan
MD & Whole Time Director5.58yrs₹5.69m0.11%
₹ 42.1m
D. Muralidharan
Chief Financial Officer4.67yrs₹3.83mno data
S. Kumar
Company Secretary & Compliance Officerno data₹944.00kno data
Partheeban Siddarth
Chief Operating Officer9.17yrs₹1.82m11.9%
₹ 4.7b
V. Natarajan
Head of Formulation & Development -Injectiblesno datano datano data
M. Narayanan
Deputy Chief Financial Officerno datano datano data

5.6yrs

Average Tenure

Experienced Management: 524742's management team is seasoned and experienced (5.6 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Sridhar Ganesan
MD & Whole Time Director5.58yrs₹5.69m0.11%
₹ 42.1m
V. Thirumalai
Non-Executive Independent Director26.33yrs₹160.00k0.32%
₹ 126.7m
D. Mishra
Non-Executive Non-Independent Director12.75yrs₹60.00kno data
C. Paarthipan
Non-Executive Chairmanno datano data18.73%
₹ 7.4b
R. Ravichandran
Non-Executive Independent Director6.42yrs₹240.00kno data
K. John
Non-Executive Independent Director6.17yrs₹140.00kno data
R. Viswanathan
Non-Executive Independent Director5.42yrs₹80.00kno data
D. Sathyanarayanan
Non-Executive Independent Director3.92yrs₹100.00kno data
C. Gariyali
Additional Non-Executive Independent Director0.58yrno datano data

6.3yrs

Average Tenure

68yo

Average Age

Experienced Board: 524742's board of directors are considered experienced (6.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Caplin Point Laboratories Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Caplin Point Laboratories Limited
  • Ticker: 524742
  • Exchange: BSE
  • Founded: 1990
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ₹39.652b
  • Shares outstanding: 75.64m
  • Website: https://www.caplinpoint.net

Number of Employees


Location

  • Caplin Point Laboratories Limited
  • Ashvich Tower
  • 3rd Floor
  • Chennai
  • Tamil Nadu
  • 600096
  • India

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
524742BSE (Mumbai Stock Exchange)YesEquity SharesININRFeb 2002
CAPLIPOINTNSEI (National Stock Exchange of India)YesEquity SharesININRFeb 2002

Biography

Caplin Point Laboratories Limited develops, manufactures, markets, and exports generic pharmaceutical formulations and branded generic products in India and internationally. It provides tablets, capsules, ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/27 12:50
End of Day Share Price2020/10/27 00:00
Earnings2020/06/30
Annual Earnings2020/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.